These data confirmed that the NF-κB mutant Eμ-Myc tumours have disrupted checkpoint kinase signalling pathway, bypassing a requirement for CHK1 activation, thus rendering them insensitive to the CHK1i. The gene discussed is MYC; the disease is neoplasm.